



Oxagen develops CRTH2 antagonists for asthma and allergy. Its most advanced product, OC000459, is in Phase IIb development and in allergic asthmatics shows excellent efficacy and safety. OC000459 is a once-daily oral product that will provide prescribers with a new, oral non-steroid option for allergic asthmatics that addresses co-morbid allergic conditions and has particular utility in younger patients.

Management Team

Mark A. Payton PhD
Chief Executive Officer

Mike Perkins MD
CMO & Clinical Development

Mick Hunter PhD
Discovery & Non-Clin Dev't

Roy Pettipher PhD
Pharmacology

Paul Foster
Finance

Board of Directors

Prof Graham Boulnois
Chairman

Mark A. Payton PhD
Chief Executive Officer

Prof John Bell

Stuart Collinson PhD

Luke Evin PhD

Anja König PhD

The Company

Oxagen Limited is a privately held UK company established in 1997 that develops anti-inflammatory medicines to treat asthma and other chronic allergic conditions. Its programmes target the CRTH2 receptor, which plays a pivotal role in the initiation and maintenance of allergic conditions, and the most advanced of its small molecule antagonists is OC000459, in Phase IIb clinical trials. The company has a strong track-record of progressing drug programmes with an experienced management team and a top-tier group of life-science investors.


Antagonism of CRTH2 is a area of intense industry interest and OC000459 is a leading compound in the field with properties that position it as a potential blockbuster. It is the most advanced asthma programme not already partnered with big pharma and so is a key licensing and acquisition target. The company has achieved clinical proof of concept in asthma, allergic rhinitis and allergic conjunctivitis along with an excellent safety profile in over 800 patients. The compound, dosed orally once-a-day, has no known drug interaction issues, a commercial manufacturing process in place, and is covered by granted patents in major markets.

Asthma opportunity



The asthma drug market is worth in excess of \$20bn but, despite a high diagnosis rate (>88%) and effective treatment of episodic attacks, chronic treatment options are only effective in subsets of patients. Evolving understanding of responder populations and more targeted medications are driving the market to stratify into patient groups with a preferred treatment option. The market has an unmet need for anti inflammatory medicines which show the same efficacy as inhaled corticosteroids but which also show better safety and oral dosing which provides high patient compliance.

Another key need is for new mechanisms with efficacy in the growing number of patients poorly controlled by inhaled corticosteroids or β -2 agonists.

OC000459 has the potential to meet both these needs. The company has identified the phenotype of patients which best respond to OC000459 and is using this, combined with its excellent safety profile, to prioritise development in younger high-responding patients with allergic asthma. This strategy takes the company directly into the patient segment with the greatest potential for initial penetration and commercial success and provides an ideal starting point for label expansion into other patient groups and indications.



Phase II b: Reduction in Respiratory Tract Infections & Exacerbations



OC000459 Safety & Efficacy in Asthma

Oxagen has conducted 14 clinical trials with OC000459 and these, and extensive toxicology studies, have shown the drug to be extraordinarily safe. In the over 800 patients dosed, the drug's adverse event profile is not significantly different to that seen with a placebo.

In the above graphic the compelling efficacy in a broad responder group is shown. In the high-responder group targeted for further trials an excellent 12.2% increase in FEV₁ (360mL, p=0.007) was seen. In this high responder group OC000459 has demonstrated efficacy in mild-moderate asthmatics that is equivalent to that published for low dose inhaled corticosteroids and superior to that published for montelukast.

During 4 and 12 week trials OC000459 has shown a positive impact on symptoms and quality of life, as well as a reduction in airway eosinophilia. Exacerbations

and respiratory tract infections are two factors believed to be crucially important in disease progression and in its 12 week trial OC000459 has shown a positive impact on both these (shown in the above figure). This feature differentiates it from current medications.

OC000459 has large commercial potential

The profile of the drug fits the unmet need in asthma for an oral drug providing steroid-like efficacy with improved safety. Fulfilling this need could produce sales of the order of those for montelukast (\$5bn, 2010) once the new therapy establishes its place in the GINA asthma prescribing guidelines. Market positions targeted are monotherapy in mild-moderate asthma and combination therapy in more severe patients underpinned by the company's proprietary data suggesting additive or synergistic activity of OC000459 in combination therapy. In addition to asthma, OC000459 has shown clinical efficacy in the large markets of allergic rhinitis and allergic

conjunctivitis and has clear potential in other allergic conditions with significant unmet need such as atopic dermatitis and eosinophilic esophagitis.

Future Development

The company is moving its OC000459 programme forward to position it for Phase III pivotal trials with a focus on monotherapy in younger allergic asthmatics and combination therapy in broader patient populations.

In parallel with developing OC000459 for asthma the company will opportunistically develop its CRTH2 antagonists in a broader range of chronic allergic settings.

Oxagen welcomes contact with potential partners or investors able to enhance clinical and commercial development of its products.

Contact

Tel: +44 (0) 1235 443300
oxagen@oxagen.co.uk